Improving Natural Product Research Translation: from Source to Clinical Trial

Abstract

While great interest in health effects of natural product (NP) including dietary supplements and foods persists, promising preclinical NP research is not consistently translating into actionable clinical trial (CT) outcomes. Generally considered the gold standard for assessing safety and efficacy, CTs, especially phase III CTs, are costly and require rigorous planning to optimize the value of the information obtained. More effective bridging from NP research to CT was the goal of a https://events-support.com/events/Natural_Product_Clinical_Trials. Participants emphasized that replicability and likelihood of successful translation depend on rigor in experimental design, interpretation, and reporting across the continuum of NP research. Discussions spanned good practices for NP characterization and quality control; use and interpretation of models (computational through in vivo) with strong clinical predictive validity; controls for experimental artefacts, especially for in vitro interrogation of bioactivity and mechanisms of action; rigorous assessment and interpretation of prior research; transparency in all reporting; and prioritization of research questions. Natural product clinical trials prioritized based on rigorous, convergent supporting data and current public health needs are most likely to be informative and ultimately affect public health. Thoughtful, coordinated implementation of these practices should enhance the knowledge gained from future NP research.

Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

“…The necessary human in vivo concentration and optimal route and formulation remain to be defined. We strongly caution against the urge to take CBD in presently available formulations as a preventative or treatment therapy at this time, especially without the knowledge of a rigorous randomized clinical trial with this natural product (23). Middle right: 85 patients took CBD before their COVID test date.…”

Innovations in the prevention and treatment of postpartum hemorrhage: Analysis of a novel medicines development pipeline database

“…There is however often a lack of regulation of supplements even if they have pharmacological properties. There is not yet compelling evidence for the effectiveness of herbal supplements for PPH prevention or treatment, and there is uncertainty about specific active compounds, biological mechanisms, and possible interactions with other medicines or supplements 39 . Thus, their potential remains uncertain, and high‐quality clinical trials are required.…”

Efficacy of Dietary Supplements to Reduce Liver Fat

“…Although preclinical studies have shown promising effects, most of these have not been translatable into clinical outcomes. Of note, lack of consistency between preclinical and clinical research further emphasizes the importance of good practices for DS studies in the preclinical setting, including optimized use of in vitro, in vivo and in silico models [ 58 ].…”